We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:
A privately held diagnostic company that has developed a proprietary blood test based on serum levels of B-cell maturation antigen (sBCMA), with positive published data, that can more accurately and rapidly monitor changes in disease status and predict both progression-free and overall survival in a wide variety of different types of liquid and solid tumors, lead indication is multiple myeloma, seeking financing
An Immuno-Oncology platform company with a broad pipeline, technology for extending half-life and bispecific antibodies available for licensing, and also seeking financing
A company with an asset in a Ph II registration trial with orphan drug designation issued in the US for PTCL, CTCL and neuroblastoma and pending in EU, available for licensing
A company with a novel monoclonal antibody, targeting LRP6/Wnt1, for the treatment of fibrotic diseases and inflammatory disorders, available for licensing.
A company with a novel orphan GI asset for the treatment of short bowel syndrome, available for licensing.
A company with a unique LAMA for Asthma & COPD with Positive Ph II Data, available for licensing
A company with a Ph IIb antibody-based therapy for the treatment of Shiga Toxin induced Hemolytic Uremic Syndrome (sHUS), an ultra-orphan disorder, available for licensing
A company with a novel Ph II mAb to treat Primary Biliary Cirrhosis and Crohn’s Disease, available for licensing
A company with a proprietary immunotherapy platform for solid tumors, with the most advanced candidate in Ph II trials, available for licensing.
A company with bispecific and monoclonal antibodies targeting FGF2 to treat HCC, Death receptors (DR4 and DR5) and high potency HuVE1 anti-VEGF mAb and HuA2T mAb to angiopoietin-2 (ang-2), available for licensing.